Nordson Corporation (NASDAQ:NDSN), a favored choice among
institutional investors, continues to show inconsistent performance. While the company's
organic growth lags, Nordson resorts to M&A strategies to support expansion, seen in their recent
acquisition of Atrion, aiming to boost medical offerings. These actions led to variations in stock holdings as Boston Financial Management LLC and many insiders sold Nordson shares. However, Copeland Capital Management LLC, Raymond James & Associates, and CHB Investment Group LLC significantly increased their shares. Nordson faced internal changes with the announcement of
Daniel Hopgood as the new CFO. Nordson's Q3
earnings surpassed estimates, but they also trimmed their sales and earnings forecast, leading to a stock price fall. Despite the headwinds, Nordson announced a
dividend increase to $0.78, marking 61 consecutive years of annual dividend increases. Investors have been cautioned about the current valuations as the rate of capital deployment doesn't match. Overall, with a five-year return of 81%, Nordson remains a potential option for future investments.
Nordson Corp NDSN News Analytics from Mon, 04 Aug 2014 07:00:00 GMT to Fri, 01 Nov 2024 07:56:08 GMT -
Rating 1
- Innovation 5
- Information 8
- Rumor 2
